Back to top
more

Syndax Pharmaceuticals (SNDX)

(Delayed Data from NSDQ)

$23.28 USD

23.28
719,171

-0.11 (-0.47%)

Updated Jul 23, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

What Makes Syndax (SNDX) a Good Fit for 'Trend Investing'

by Zacks Equity Research

Syndax (SNDX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Can Syndax (SNDX) Climb 39% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 39.1% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Incyte (INCY) Outperforms YTD: Will the Momentum Continue?

by Zacks Equity Research

Incyte (INCY) outperforms the biotech industry in the year so far and the momentum should continue in 2023 as well.

Blueprint Medicines (BPMC) Files Ayvakit sNDA for Indolent SM

by Zacks Equity Research

Blueprint Medicines (BPMC) submits a supplemental new drug application for its lead drug, Ayvakit, for the treatment of indolent systemic mastocytosis to the FDA.

Regeneron's (REGN) Libtayo Gets EC Nod for Cervical Cancer

by Zacks Equity Research

Regeneron (REGN) gets EC's approval for the label expansion of PD-1 inhibitor Libtayo for the treatment of adult patients with recurrent or metastatic cervical cancer.

Teva Pharmaceutical (TEVA) Names Richard Francis as New CEO

by Zacks Equity Research

Teva Pharmaceutical (TEVA) appoints Richard Francis as the company's new president and chief executive officer, effective from Jan 1, 2023.

Apellis (APLS) Rises on FDA Acceptance of NDA Amendment for GA

by Zacks Equity Research

The FDA accepts Apellis' (APLS) major amendment to the NDA for pegcetacoplan to treat geographic atrophy secondary to age-related macular degeneration. A decision is now due on Feb 26, 2023. Stock up.

Gilead (GILD) Outperforms YTD: Will It Retain the Momentum?

by Zacks Equity Research

Biotech giant Gilead (GILD) outperforms the industry and the S&P 500 Index as its core business maintains momentum despite volatility.

Editas (EDIT) Pauses Eye Disease Study on EDIT-101, Stock Down

by Zacks Equity Research

Editas (EDIT) pauses enrollment in the phase I/II BRILLIANCE study evaluating EDIT-101 for treating blindness due to Leber congenital amaurosis 10. Stock falls.

Immunovant (IMVT) Rises More Than 150% in 3 Months: Here's How

by Zacks Equity Research

Immunovant (IMVT) is making good progress with its lead pipeline candidate, batoclimab, which is being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.

Bayer (BAYRY) Eylea Label Extension Gets CHMP Positive Opinion

by Zacks Equity Research

Bayer (BAYRY) gets positive recommendation from the CHMP for label extension of ophthalmology drug Eylea for the treatment of preterm infants with retinopathy of prematurity.

Viatris (VTRS) Wins in Court Against AstraZeneca's Symbicort

by Zacks Equity Research

Viatris (VTRS) and its partner win a court decision that invalidates branded drug Symbicort's patent and opens the door for them to launch their generic version of the drug.

Clovis (CLVS) Plummets on News of Possible Bankruptcy Filing

by Zacks Equity Research

Clovis (CLVS) tanks following the possibility of a bankruptcy filing in the near term after recent regulatory developments impacted current revenues and the commercial potential of Rubraca.

Recent Price Trend in Syndax (SNDX) is Your Friend, Here's Why

by Zacks Equity Research

Syndax (SNDX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Does Syndax (SNDX) Have the Potential to Rally 67% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 66.9% in Syndax (SNDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Syndax (SNDX) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Can Syndax (SNDX) Climb 48% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 47.7% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Incyte (INCY) Collaborates With Syndax for Chronic GVHD Candidate

by Zacks Equity Research

Incyte (INCY) collaborates with Syndax to develop and commercialize axatilimab for chronic graft-versus-host disease and other fibrotic diseases.

Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Syndax (SNDX) delivered earnings and revenue surprises of 40.54% and -24.20%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Syndax Pharmaceuticals (SNDX) Q2 Earnings Expected to Decline

by Zacks Equity Research

Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Syndax (SNDX) Moves 10.7% Higher: Will This Strength Last?

by Zacks Equity Research

Syndax (SNDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Syndax's (SNDX) Axatilimab Gets FDA's Orphan Drug Tag for IPF

by Zacks Equity Research

The FDA grants orphan drug designation to Syndax's (SNDX) axatilimab for the treatment of patients with idiopathic pulmonary fibrosis. Shares up.

Syndax's (SNDX) Axatilimab Gets FDA's Orphan Drug Tag for GVHD

by Zacks Equity Research

The FDA bestows an orphan drug designation on Syndax's (SNDX) axatilimab for the treatment of patients with chronic graft versus host disease. Shares up.

Implied Volatility Surging for Syndax Pharmaceuticals (SNDX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Syndax Pharmaceuticals (SNDX) stock based on the movements in the options market lately.

Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Syndax (SNDX) delivered earnings and revenue surprises of -9.80% and -0.26%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?